# Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer

> **NCT03659448** · PHASE3 · RECRUITING · sponsor: **Surgimab** · enrollment: 300 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** SGM-101

## Key facts

- **NCT ID:** NCT03659448
- **Lead sponsor:** Surgimab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-06-17
- **Primary completion:** 2024-11
- **Final completion:** 2024-12
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03659448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03659448, "Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03659448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*